Search clinical trials for: ADH -1 and carboplatin

Total 16966 results

Adherex Technologies, Inc.
US Oncology Research

Completed

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Neoplasms

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Malignant Solid Neoplasm

United States, Puerto Rico
Adherex Technologies, Inc.

Terminated

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Neoplasms

United States
Adherex Technologies, Inc.

Completed

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Neoplasms

United States, Canada
Children's Hospital Medical Center, Cincinnati

Terminated

ADHD/Me Bibliotherapy Study

Attention Deficit Hyperactivity Disorder

United States
National Cancer Institute (NCI)

Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditions

United States
Adherex Technologies, Inc.

Completed

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Neoplasms

Italy, Switzerland
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Hematopoietic and Lymphoid Cell Neoplasm | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
National Cancer Institute (NCI)
Abbott

Active, not recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Liver Failure | Melanoma | Renal Failure | Breast Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Esophageal Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Malignant Head and Neck Neoplasm | Carcinoma of Unknown Primary | Malignant Testicular...

United States
Northwestern University
National Cancer Institute (NCI)

Withdrawn

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Breast Inflammatory Carcinoma

United States
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Jonsson Comprehensive Cancer Center
TetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaborators

Withdrawn

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma

United States
Windy Hill Medical, Inc.

Unknown

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

Ductal Carcinoma In Situ

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Sai Life Sciences

Completed

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Solid Tumors

United States
Instituto Nacional de Cancerologia de Mexico

Recruiting

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

Lung Cancer | Sarcopenia | Toxicity

Mexico
James Elder

Completed

Carboplatin in Treating Patients With Recurrent High-Grade Gliomas

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Recurrent Adult Brain Tumor

United States
Abbott

Terminated

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Lymphadenopathy | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Prostate Small Cell Carcinoma

United States
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
National Cancer Institute (NCI)

Completed

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Hereditary Breast and Ovarian Cancer Syndrome | Adult Solid Neoplasm | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
National Cancer Institute (NCI)

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
University of Washington
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7 | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Primary Peritoneal Cancer... and other conditions

United States
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

Gastroesophageal Junction Adenocarcinoma | Stage IB Esophageal Adenocarcinoma AJCC v7 | Stage II Esophageal Adenocarcinoma AJCC v7 | Stage IIA Esophageal Adenocarcinoma AJCC v7 | Stage IIB Esophageal Adenocarcinoma AJCC v7 | Stage IIIA Esophageal Adenocarcinoma AJCC v7 | Stage IIIB Esophageal...

United States
Henry Ford Health System

Recruiting

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Glioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Malignant Astrocytoma

United States
Marcelo Bonomi

Recruiting

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditions

United States
University of Washington
National Cancer Institute (NCI); United States Department of Defense

Recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...

United States
The Netherlands Cancer Institute

Completed

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (REVIVAL)

Breast Cancer | Ovarian Cancer | Advanced Cancer

Netherlands
Eli Lilly and Company

Completed

Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cancer

Germany, Argentina, Canada, Poland, Sweden
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Lung Adenocarcinoma | Minimally Invasive Lung Adenocarcinoma | Malignant Pleural Effusion | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Malignant Pericardial Effusion | Lung Adenosquamous Carcinoma

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
National Cancer Institute (NCI)

Completed

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage... and other conditions

United States
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed Subtype

United States

Search clinical trials for: ADH -1 and carboplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations